bearish

Re-Examine the Outlook and Investment Strategy for China Biotech and CXO

Xinyao has highlighted this Insight as a Top Pick
254 Views11 May 2022 08:55
The investment logic of China biotech has broken due to dilemma of domestic policy and internationalization risk.CXO couldn't sustain high valuation and strong growth since its best time has been over
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
x